Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target-HTN: Safety and Efficacy of MLS-101 (Lorundrostat) in Uncontrolled Hypertension
NCT05001945Phase 2Completed
- Sponsor
- Mineralys Therapeutics
- Start
- Jul 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lorundrostat in hypertension (HTN), sponsored by Mineralys Therapeutics. Started Jul 2021; status: completed.
02
Drugs
lorundrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05001945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001945.